Step 1: Clinical indication. Inferior vena cava interruption with a filter is reserved for thromboembolic disease when blood thinners are contraindicated or have failed. The filter sits in the lumen of the IVC and physically intercepts ascending clots.
Step 2: Benefits offered. Because large dislodged thrombi are captured, the patient is protected from a major pulmonary embolism. This protection translates into fewer symptoms, a lower risk of fatal embolic events (prolonging life), and reduced ongoing damage to the native vessels.
Step 3: The key limitation. The mesh of the filter has finite pore size. Very small clots slip straight through and are never arrested. Therefore the device does nothing for emboli of negligible size, which is precisely why that choice is the odd one out.
Step 4: Eliminating the others. Reducing symptoms, prolonging life, and preventing progression of disease in the native vessels are all genuine goals of filter placement, so they are valid uses and cannot be the exception.
Hence the statement that does not describe a use of the IVC filter is the one about negligible-size emboli.
\[\boxed{\text{Negligible size of emboli}}\]